Investigating the Potential of Bevacizumab in Other Indications: Metastatic Renal Cell, Non-Small Cell Lung, Pancreatic and Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|69|3|46-56

ISSN： 0030-2414

Source： Oncology, Vol.69, Iss.3, 2005-11, pp. : 46-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 62-66

Karger

Access to resources Recommend Favorite

Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 37, Iss. 5, 2014-04 ,pp. : 262-265

Karger

Access to resources Recommend Favorite

Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 350-358

Karger

Access to resources Recommend Favorite

Docetaxel in non-small cell lung cancer

By Souquet Pierre-Jean   Geriniere Laurence  

Therapy, Vol. 3, Iss. 5, 2006-09 ,pp. : 579-590

Future Medicine

Access to resources Recommend Favorite

Ifosfamide in Non-Small Cell Lung Cancer

By  

Oncology, Vol. 65, Iss. 2, 2003-11 ,pp. : 50-54

Karger

Access to resources Recommend Favorite